Rituximab-induced interstitial lung disease: five case reports

Rituximab (RTX), a mouse/human chimeric anti-CD20 IgG1 monoclonal antibody has been effectively used as a single agent or in combination with chemotherapy regimen to treat lymphoma since 1997. In addition, it has been used to treat idiopathic thrombocytopenic purpura, systemic lupus erythematous, rh...

Descripción completa

Detalles Bibliográficos
Autores principales: Naqibullah, Matiuallah, Shaker, Saher B., Bach, Karen S., Bendstrup, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629765/
https://www.ncbi.nlm.nih.gov/pubmed/26557260
http://dx.doi.org/10.3402/ecrj.v2.27178
_version_ 1782398627746938880
author Naqibullah, Matiuallah
Shaker, Saher B.
Bach, Karen S.
Bendstrup, Elisabeth
author_facet Naqibullah, Matiuallah
Shaker, Saher B.
Bach, Karen S.
Bendstrup, Elisabeth
author_sort Naqibullah, Matiuallah
collection PubMed
description Rituximab (RTX), a mouse/human chimeric anti-CD20 IgG1 monoclonal antibody has been effectively used as a single agent or in combination with chemotherapy regimen to treat lymphoma since 1997. In addition, it has been used to treat idiopathic thrombocytopenic purpura, systemic lupus erythematous, rheumatoid arthritis, and autoimmune hemolytic anemia. Recently, RTX has also been suggested for the treatment of certain connective tissue disease–related interstitial lung diseases (ILD) and hypersensitivity pneumonitis. Rare but serious pulmonary adverse reactions are reported. To raise awareness about this serious side effect of RTX treatment, as the indication for its use increases with time, we report five cases of probable RTX-ILD and discuss the current literature on this potentially lethal association.
format Online
Article
Text
id pubmed-4629765
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Co-Action Publishing
record_format MEDLINE/PubMed
spelling pubmed-46297652015-11-09 Rituximab-induced interstitial lung disease: five case reports Naqibullah, Matiuallah Shaker, Saher B. Bach, Karen S. Bendstrup, Elisabeth Eur Clin Respir J Case Report Rituximab (RTX), a mouse/human chimeric anti-CD20 IgG1 monoclonal antibody has been effectively used as a single agent or in combination with chemotherapy regimen to treat lymphoma since 1997. In addition, it has been used to treat idiopathic thrombocytopenic purpura, systemic lupus erythematous, rheumatoid arthritis, and autoimmune hemolytic anemia. Recently, RTX has also been suggested for the treatment of certain connective tissue disease–related interstitial lung diseases (ILD) and hypersensitivity pneumonitis. Rare but serious pulmonary adverse reactions are reported. To raise awareness about this serious side effect of RTX treatment, as the indication for its use increases with time, we report five cases of probable RTX-ILD and discuss the current literature on this potentially lethal association. Co-Action Publishing 2015-05-21 /pmc/articles/PMC4629765/ /pubmed/26557260 http://dx.doi.org/10.3402/ecrj.v2.27178 Text en © 2015 Matiuallah Naqibullah et al. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.
spellingShingle Case Report
Naqibullah, Matiuallah
Shaker, Saher B.
Bach, Karen S.
Bendstrup, Elisabeth
Rituximab-induced interstitial lung disease: five case reports
title Rituximab-induced interstitial lung disease: five case reports
title_full Rituximab-induced interstitial lung disease: five case reports
title_fullStr Rituximab-induced interstitial lung disease: five case reports
title_full_unstemmed Rituximab-induced interstitial lung disease: five case reports
title_short Rituximab-induced interstitial lung disease: five case reports
title_sort rituximab-induced interstitial lung disease: five case reports
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4629765/
https://www.ncbi.nlm.nih.gov/pubmed/26557260
http://dx.doi.org/10.3402/ecrj.v2.27178
work_keys_str_mv AT naqibullahmatiuallah rituximabinducedinterstitiallungdiseasefivecasereports
AT shakersaherb rituximabinducedinterstitiallungdiseasefivecasereports
AT bachkarens rituximabinducedinterstitiallungdiseasefivecasereports
AT bendstrupelisabeth rituximabinducedinterstitiallungdiseasefivecasereports

Ejemplares similares